Potential drug interactions and chemotoxicity in older patients with cancer receiving chemotherapy

Journal of Geriatric Oncology

Volumn 5, Issue 3, 2014, Pages 307-314

  Popa, Mihaela A ^a   Wallace, Kristie J ^b   Brunello, Antonella ^c   Extermann, Martine ^d   Balducci, Lodovico ^d  

^a Biovest International   (United States)

^b Edward White Hospital   (United States)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Chemotherapy; Chemotoxicity; CTCAE; Drug Interaction Facts ; Drug interaction software; Drug interactions; Elderly; Geriatric oncology

Indexed keywords

ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DIGOXIN; DOXORUBICIN; ETOPOSIDE; FLUCONAZOLE; FLUOROURACIL; FUROSEMIDE; HERBACEOUS AGENT; METHOTREXATE; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; PHENYTOIN; VINCRISTINE; WARFARIN; PLANT MEDICINAL PRODUCT; PRESCRIPTION DRUG;

ADVERSE DRUG REACTION; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CONVENIENCE SAMPLE; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PREVALENCE; PRIORITY JOURNAL; SOLID TUMOR; UNSPECIFIED SIDE EFFECT; DRUG INTERACTION; NEOPLASMS; RETROSPECTIVE STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIFUNGAL AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; NEOPLASMS; NONPRESCRIPTION DRUGS; PLANT PREPARATIONS; PRESCRIPTION DRUGS; RETROSPECTIVE STUDIES;

EID: 84904964958     PISSN: 18794068     EISSN: 18794076     Source Type: Journal    
DOI: 10.1016/j.jgo.2014.04.002     Document Type: Article

References (64)

1. Steinman M.A., Lee S.J., John Boscardin W., Miao Y., Fung K.Z., Moore K.L., et al. Patterns of multimorbidity in elderly veterans. J Am Geriatr Soc 2012, 60(10):1872-1880. [Epub 2012/10/06].
2. Pugh M.J., Starner C.I., Amuan M.E., Berlowitz D.R., Horton M., Marcum Z.A., et al. Exposure to potentially harmful drug-disease interactions in older community-dwelling veterans based on the Healthcare Effectiveness Data and Information Set quality measure: who is at risk?. J Am Geriatr Soc 2011, 59(9):1673-1678. [Epub 2011/08/13].
3. Walter L.C., Lindquist K., Nugent S., Schult T., Lee S.J., Casadei M.A., et al. Impact of age and comorbidity on colorectal cancer screening among older veterans. Ann Intern Med 2009, 150(7):465-473. [Epub 2009/04/08].
4. Extermann M., Wedding U. Comorbidity and geriatric assessment for older patients with hematologic malignancies: a review of the evidence. J Geriatr Oncol 2012, 3(1):49-57.
5. Jorgensen T.L., Herrstedt J., Friis S., Hallas J. Polypharmacy and drug use in elderly Danish cancer patients during 1996 to 2006. J Geriatr Oncol 2012, 3(1):33-40.
6. Si P., Koo K.N., Poon D., Chew L. Knowledge of prescription medications among cancer patients aged 65years and above. J Geriatr Oncol 2012, 3(2):120-130.
7. Clarfield A.M., Bergman H., Kane R. Fragmentation of care for frail older people - an international problem. Experience from three countries: Israel, Canada, and the United States. J Am Geriatr Soc 2001, 49(12):1714-1721.
8. Steinman M.A., Hanlon J.T. Managing medications in clinically complex elders: "There's got to be a happy medium". JAMA 2010, 304(14):1592-1601. [Epub 2010/10/14].
9. Qato D.M., Alexander G.C., Conti R.M., Johnson M., Schumm P., Lindau S.T. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 2008, 300(24):2867-2878. [Epub 2008/12/26].
10. Balducci L., Goetz-Parten D., Steinman M.A. Polypharmacy and the management of the older cancer patient. Ann Oncol 2013, (24 Suppl 7):vii36-vii40. [Epub 2013/09/06].
11. Hanigan M.H., Dela Cruz B.L., Thompson D.M., Farmer K.C., Medina P.J. Use of prescription and nonprescription medications and supplements by cancer patients during chemotherapy: questionnaire validation. J Oncol Pharm Pract 2008, 14(3):123-130. [Epub 2008/08/23].
12. Puts M.T., Costa-Lima B., Monette J., Girre V., Wolfson C., Batist G., et al. Medication problems in older, newly diagnosed cancer patients in Canada: how common are they? A prospective pilot study. Drugs Aging 2009, 26(6):519-536. [Epub 2009/07/14].
13. Prithviraj G.K., Koroukian S., Margevicius S., Berger N.A., Bagai R., Owusu C. Patient characteristics associated with polypharmacy and inappropriate prescribing of medications among older adults with cancer. J Geriatr Oncol 2012, 3(3):228-237.
14. Riechelmann R.P., Tannock I.F., Wang L., Saad E.D., Taback N.A., Krzyzanowska M.K. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 2007, 99(8):592-600. [Epub 2007/04/19].
15. van Leeuwen R.W., Swart E.L., Boven E., Boom F.A., Schuitenmaker M.G., Hugtenburg J.G. Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method. Ann Oncol 2011, 22(10):2334-2341. [Epub 2011/02/24].
16. Riechelmann R.P., Zimmermann C., Chin S.N., Wang L., O'Carroll A., Zarinehbaf S., et al. Potential drug interactions in cancer patients receiving supportive care exclusively. J Pain Symptom Manage 2008, 35(5):535-543. [Epub 2008/02/05].
17. Flood K.L., Carroll M.B., Le C.V., Brown C.J. Polypharmacy in hospitalized older adult cancer patients: experience from a prospective, observational study of an oncology - acute care for elders unit. Am J Geriatr Pharmacother 2009, 7(3):151-158. [Epub 2009/07/21].
18. Sokol K.C., Knudsen J.F., Li M.M. Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management. J Clin Pharm Ther 2007, 32(2):169-175. [Epub 2007/03/27].
19. Wallace K., Overcash J., Yoder J., Vranas P., Extermann M. Influence of concomitant medications on toxicity from chemotherapy in elderly patients. Focus on cytochrome P-450 inhibition and protein binding effects. Proc Am Soc Clin Oncol 2005, 23(16S):735s.
20. Drug interactions facts. Wolters and Kluwer Health Version 4.0. http://www.factsandcomparissons.com.
21. Barrons R. Evaluation of personal digital assistant software for drug interactions. Am J Health Syst Pharm 2004, 61(4):380-385. [Epub 2004/03/12].
22. Wong C.M., Ko Y., Chan A. Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: profiling and comparison of two drug compendia. Ann Pharmacother 2008, 42(12):1737-1748. [Epub 2008/11/27].
23. Extermann M., Chen H., Cantor A.B., Corcoran M.B., Meyer J., Grendys E., et al. Predictors of tolerance to chemotherapy in older cancer patients: a prospective pilot study. Eur J Cancer 2002, 38(11):1466-1473.
24. Hurria A., Hurria A., Brogan K., Panageas K.S., Pearce C., Norton L., et al. Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer. Drugs Aging 2005, 22(9):785-791.
25. Intragumtornchai T., Sutheesophon J., Sutcharitchan P., Swasdikul D. A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2000, 37(3-4):351-360.
26. Marinello R., Marenco D., Roglia D., Stasi M.F., Ferrando A., Ceccarelli M., et al. Predictors of treatment failures during chemotherapy: a prospective study on 110 older cancer patients. Arch Gerontol Geriatr 2009, 48:222-226.
27. Rogatko A., Babb J.S., Wang H., Slifker M.J., Hudes G.R. Patient characteristics compete with dose as predictors of acute treatment toxicity in early phase clinical trials. Clin Cancer Res 2004, 10(14):4645-4651.
28. Extermann M., Bonetti M., Sledge G.W., O'Dwyer P.J., Bonomi P., Benson A.B. MAX2 - a convenient index to estimate the average per patient risk for chemotherapy toxicity; validation in ECOG trials. Eur J Cancer 2004, 40(8):1193-1198.
29. Extermann M., Boler I., Reich R.R., Lyman G.H., Brown R.H., DeFelice J., et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer 2012, 118(13):3377-3386. [Epub 2011/11/11].
30. Hurria A., Brogan K., Panageas K.S., Pearce C., Norton L., Jakubowski A., et al. Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat 2005, 92(2):151-156.
31. Gronberg B., Jordhoy M., Sundstrom S. The prognostic value of comorbidity assessed with the Cumulative Illness Rating Scale for Geriatrics (CIRS-G) in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2008, 26(15s):503s.
32. Hurria A., Togawa K., Mohile S.G., Owusu C., Klepin H.D., Gross C.P., et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011, 29(25):3457-3465. [Epub 2011/08/04].
33. Zauderer M., Patil S., Hurria A. Feasibility and toxicity of dose-dense adjuvant chemotherapy in older women with breast cancer. Breast Cancer Res Treat 2009, 117(1):205-210. [Epub 2008/07/16].
34. Bjerrum L., Andersen M., Petersen G., Kragstrup J. Exposure to potential drug interactions in primary health care. Scand J Prim Health Care 2003, 21(3):153-158.
35. Hanlon J.T., Schmader K.E., Koronkowski M.J., Weinberger M., Landsman P.B., Samsa G.P., et al. Adverse drug events in high risk older outpatients. J Am Geriatr Soc 1997, 45(8):945-948.
36. Hanlon J.T., Weinberger M., Samsa G.P., Schmader K.E., Uttech K.M., Lewis I.K., et al. A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. Am J Med 1996, 100(4):428-437.
37. Zarowitz B.J., Stebelsky L.A., Muma B.K., Romain T.M., Peterson E.L. Reduction of high-risk polypharmacy drug combinations in patients in a managed care setting. Pharmacotherapy 2005, 25(11):1636-1645.
38. Schmader K.E., Hanlon J.T., Pieper C.F., Sloane R., Ruby C.M., Twersky J., et al. Effects of geriatric evaluation and management on adverse drug reactions and suboptimal prescribing in the frail elderly. Am J Med 2004, 116(6):394-401.
39. Brunello A., Kapoor R., Extermann M. Hyperglycemia during chemotherapy for hematologic and solid tumors is correlated with increased toxicity. Am J Clin Oncol 2011, 34(3):292-296. [Epub 2010/07/14].
40. Popa M., Wallace K., Brunello A., Extermann M. The impact of polypharmacy on toxicity from chemotherapy in elderly patients: focus on cytochrome P-450 inhibition and protein binding effects. Proc Am Soc Clin Oncol 2008, 26(15S):503s.
41. Shayne M., Crawford J., Dale D.C., Culakova E., Lyman G.H. Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat 2006, 100(3):255-262. [Epub 2006/05/18].
42. Frasci G., Lorusso V., Panza N., Comella P., Nicolella G., Bianco A., et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2000, 18(13):2529-2536.
43. Fader A.N., von Gruenigen V., Gibbons H., Abushahin F., Starks D., Markman M., et al. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients. Gynecol Oncol 2008, 109(1):33-38. [Epub 2008/02/12].
44. The prognostic value of comorbidity assessed with the Cumulative Illness Rating Scale for Geriatrics (CIRS-G) in patients with advanced non-small cell lung cancer (NSCLC). Annual Meeting of the American Society of Clinical Oncology; 2008; Chicago, IL: Journal of Clinical Oncology 2008, B. Gronberg, M. Jordhoy, S. Sundstrom (Eds.).
45. Gillies J., Hung K.A., Fitzsimons E., Soutar R. Severe vincristine toxicity in combination with itraconazole. Clin Lab Haematol 1998, 20(2):123-124.
46. Marr K.A., Leisenring W., Crippa F., Slattery J.T., Corey L., Boeckh M., et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004, 103(4):1557-1559.
47. Beijnen J.H., Schellens J.H. Drug interactions in oncology. Lancet Oncol 2004, 5(8):489-496.
48. Maiche A.G. Acute renal failure due to concomitant action of methotrexate and indomethacin. Lancet 1986, 1(8494):1390.
49. Stockley I.H. Methotrexate-NSAID interactions. Drug Intell Clin Pharm 1987, 21(6):546.
50. Brummett R.E. Effects of antibiotic-diuretic interactions in the guinea pig model of ototoxicity. Rev Infect Dis 1981, 3(Suppl.):S216-S223.
51. Brummett R.E., Bendrick T., Himes D. Comparative ototoxicity of bumetanide and furosemide when used in combination with kanamycin. J Clin Pharmacol 1981, 21(11-12 Pt 2):628-636.
52. Aki Z., Kotiloglu G., Ozyilkan O. A patient with a prolonged prothrombin time due to an adverse interaction between 5-fluorouracil and warfarin. Am J Gastroenterol 2000, 95(4):1093-1094.
53. Davis D.A., Fugate S.E. Increasing warfarin dosage reductions associated with concurrent warfarin and repeated cycles of 5-fluorouracil therapy. Pharmacotherapy 2005, 25(3):442-447.
54. Le A.T., Hasson N.K., Lum B.L. Enhancement of warfarin response in a patient receiving etoposide and carboplatin chemotherapy. Ann Pharmacother 1997, 31(9):1006-1008.
55. Riechelmann R.P., Saad E.D. A systematic review on drug interactions in oncology. Cancer Invest 2006, 24(7):704-712.
56. Kuhlmann J., Zilly W., Wilke J. Effects of cytostatic drugs on plasma level and renal excretion of beta-acetyldigoxin. Clin Pharmacol Ther 1981, 30(4):518-527.
57. Dofferhoff A.S., Berendsen H.H., vd Naalt J., Haaxma-Reiche H., Smit E.F., Postmus P.E. Decreased phenytoin level after carboplatin treatment. Am J Med 1990, 89(2):247-248.
58. Chan A., Tan S.H., Wong C.M., Yap K.Y., Ko Y. Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: a Delphi survey of oncology pharmacists. Clin Ther 2009, 31(Pt 2):2379-2386. [Epub 2010/01/30].
59. Extermann M. Integrating a geriatric evaluation in the clinical setting. Semin Radiat Oncol 2012, 22(4):272-276. [Epub 2012/09/19].
60. Aaldriks A.A., Maartense E., le Cessie S., Giltay E.J., Verlaan H., van der Geest L.G.M., et al. Predictive value of geriatric assessment for patients older than 70years, treated with chemotherapy. Crit Rev Oncol Hematol 2011, 79(2):205-212.
61. Hines L.E., Murphy J.E. Potentially harmful drug-drug interactions in the elderly: a review. Am J Geriatr Pharmacother 2011, 9(6):364-377. [Epub 2011/11/15].
62. Popa M., Wallace K., Brunello A., Extermann M. The impact of polypharmacy on toxicity from chemotherapy in elderly patients: focus on cytochrome P-450 inhibition and protein binding effects. J Clin Oncol 2008, 26(15S):9505.
63. Singh R.R., Malaviya A.N., Pandey J.N., Guleria J.S. Fatal interaction between methotrexate and naproxen. Lancet 1986, 1(8494):1390.
64. Yap K.Y., Chui W.K., Chan A. Drug interactions between chemotherapeutic regimens and antiepileptics. Clin Ther 2008, 30(8):1385-1407.